Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant Bacteroides ovatus expressing anti-BFT1 peptide
- Development stage
- Preclinical
- Lead developer
- University of Washington
- Modality
- Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
recombinant Bacteroides ovatus expressing anti-BFT1 peptide is an engineered probiotic strain of *Bacteroides ovatus* designed to prevent and treat enteric diseases caused by enterotoxigenic *Bacteroides fragilis* (ETBF). The probiotic is genetically modified to constitutively express and secrete in silico-designed short peptides that bind and neutralize *B. fragilis* toxin 1 (BFT1, or fragilysin). By blocking BFT1, the therapeutic prevents toxin-induced damage to the intestinal epithelium, including E-cadherin cleavage, F-actin rearrangement, and inflammatory cytokine responses. It is being developed by the University of Washington for the potential treatment of acute diarrheal illness and associated poor growth outcomes in children.
- Other names
- rB. ovatusrecombinant B. ovatus expressing anti-BFT1 peptiderecombinant Bacteroides ovatus
Beyond the preview
Go deeper on recombinant Bacteroides ovatus expressing anti-BFT1 peptide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant Bacteroides ovatus expressing anti-BFT1 peptide.